Brandelyn N. Pitcher

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib

Lisa A. Carey, Donald A. Berry, Constance Cirrincione et al. · Journal of Clinical Oncology · 2015 · 429 citations · Full text

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

Nancy L. Bartlett, Wyndham H. Wilson, Sin‐Ho Jung et al. · Journal of Clinical Oncology · 2019 · 395 citations

Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)

John P. Leonard, Sin‐Ho Jung, Jeffrey L. Johnson et al. · Journal of Clinical Oncology · 2015 · 179 citations · Full text

PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)

Minetta C. Liu, Brandelyn N. Pitcher, Elaine R. Mardis et al. · npj Breast Cancer · 2016 · 111 citations · Full text

Predicting response and survival in chemotherapy-treated triple-negative breast cancer

Aleix Prat, Aňa Lluch, Joan Albanell et al. · British Journal of Cancer · 2014 · 110 citations · Full text